CIS-DIAMMINEDICHLOROPLATINUM II
BRCA2 Mutation Carrier
The University of Texas Health Science Center at San AntonioSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the BRCA2 Mutation Carrier cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Veliparib The University of Texas Health Science Center at San Antonio | Phase 2 | BB |
Vinorelbine The University of Texas Health Science Center at San Antonio | Phase 2 | BB |
Cediranib M.D. Anderson Cancer Center | Phase 2 | B |
Metformin Alliance for Clinical Trials in Oncology | Phase 3 | B |
Telapristone Acetate Northwestern University | Phase 2 | B |
View all 9 →
Same molecule, other indications
CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →